Search
Aug 27
Health 2035 Summit: Roivant CEO Matt Gline on why he believes this is a good time to be hunting for assets on the shelves of big pharma, and upcoming catalysts
He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts...
Jan 22
Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage
Matt Gline reflects on learnings from the Telavant success, and why he thinks Immunovant's FcRn might be best in class.
.png){kind=logo}
